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METHODS: A randomized, prospective, parallel, dou-
ble-blind, double-dummy trial was conducted to deter-
mine the analgesic efficacy and time to onset of analgesia
following IV and IM administration of ketorolac (15 mg
and 30 mg), and oral ibuprofen 800 mg (N  100). Pain
intensity was evaluated using visual analog and verbal
rating scales. 
RESULTS: Patients who received ketorolac (30 mg IV)
showed a greater decrease in pain intensity compared with
patients in all other groups (p  0.005). Fifty percent pain
relief before the end of the study was achieved by 50% of
patients in one group only: ketorolac (30 mg IV). 
CONCLUSION: Ketorolac (30 mg IV) provided a greater
degree of pain relief and a quicker time to onset of analge-
sia than all other groups. There were no differences in an-
algesic efficacy between ketorolac (30 mg IM), ketorolac
(15 mg IM), ketorolac (15 mg IV) and ibuprofen 800 mg.
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OBJECTIVE: The purpose of this study was to compare
the 5-year costs of using various sequences of contracep-
tive methods. 
METHOD: We constructed a series of 20 Markov mod-
els, each describing a different sequence of contraceptive
choices over a 5-year time horizon, including one or
more oral contraceptives (COC or POP), Depo Provera,
the Copper IUD (Multiload Cu375 or Nova T), Mirena
and male or female sterilization as a backup option. 
RESULTS: Contraceptive sequences incorporating Mirena
are substantially more effective than those with the stan-
dard copper IUD at little or no additional cost to the
healthcare payer over a 5-year period, whether Mirena is
used as a first-line or second-line contraceptive method.
The higher up-front acquisition cost of the device com-
pared with the standard copper IUD is compensated by its
greater effectiveness in reducing the incidence of costly un-
planned pregnancy. Contraceptive sequences with Mirena,
Depo Provera or the IUD first-line are more effective and
less costly than sequences beginning with oral contracep-
tives first-line. Compared with no contraceptive method,
Mirena has the potential to realise net savings to the
Health Funding Authority of about $2200 per woman
over a 5-year period through preventing costly unplanned
pregnancy. 
CONCLUSIONS: These findings support Mirena either as
first-line contraception for women who have completed
their families or as a second-line contraceptive method for
women for whom the IUD or oral contraception is inap-
propriate or who cannot tolerate other methods.
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OBJECTIVE: The purpose of this analysis was to deter-
mine the cost impact of obtaining emergency contracep-
tion directly from a pharmacist in Washington state. 
METHODS: Using a range of published rates of concep-
tion and emergency contraceptive effectiveness, the num-
ber of pregnancies prevented was estimated for 6267
women obtaining emergency contraception from a phar-
macist in Washington state from February 25, 1998 to
December 31, 1998. The direct costs of the prevented
pregnancies were estimated using published data updated
to 1998 dollars for private and public payers. Both an
averted-birth and a delayed-birth assumption were em-
ployed. Resulting costs were compared to the cost of the
emergency contraception to assess the cost impact. 
RESULTS: In the base case, emergency contraception
prevented 334 pregnancies. In the public payer, averted-
birth model, use of emergency contraception resulted in
$482,851 saved. The public payer, delayed-birth model
resulted in cost savings of $123,801. In the private payer,
averted-birth model, emergency contraception resulted in
cost savings of $1,511,382. The private payer, delayed-
birth model resulted in cost savings of $552,134. When
analyzing the best and worst case scenarios, savings from
use of emergency contraception ranged from $107,769
to $7,430,724. The broad range of cost savings is attrib-
utable to the heterogeneity of conception and effective-
ness rates assumed. 
CONCLUSION: Emergency contraception prevents many
unintended pregnancies. Under most assumptions, the di-
rect cost of emergency contraception is lower than the di-
rect cost of unintended pregnancies. Emergency contracep-
tion provided directly by pharmacists is a cost saving
method of preventing unintended pregnancies.
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Impairment of quality of life (QoL) of menopausal women
has often been demonstrated using condition-specific QoL
instruments. However, condition-specific QoL data are of
relatively limited usefulness in deciding whether treat-
ments of proven efficacy such as hormone replacement
